# Evaluating Novel Therapies in ctDNA Positive GI Cancers

Source: https://onco.cc/trials/nct05482516/  
OnCo record `nct05482516` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of atezolizumab and bevacizumab in gallbladder cancer and other biliary tract cancers, run by Georgetown University, now recruiting.

## Summary

Evaluating Novel Therapies in ctDNA Positive GI Cancers is a phase 3 interventional study registered as NCT05482516 by Georgetown University, with a registry enrolment figure of 20 participants, started 2023-03-29 and due to reach its primary completion in 2026-12. Interventions recorded: Atezolizumab, Bevacizumab. Conditions listed: Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: MRD-GI
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05482516
- Phase: 3
- Setting: Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease
- Sponsor: Georgetown University
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT05482516: https://clinicaltrials.gov/study/NCT05482516

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05482516.json